PRVA EBITDA | Privia Health Group, Inc.

Privia Health Group, Inc. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

Privia Health Group, Inc. ebitda for the quarter ending 2026-06-30 was $15.13M, a 155.60% increase year-over-year.
Privia Health Group, Inc. ebitda for the quarter ending 2026-03-31 was $10.7M, a 50.34% increase year-over-year.
Privia Health Group, Inc. ebitda for the quarter ending 2025-12-31 was $13.94M, a 96.82% increase year-over-year.
Privia Health Group, Inc. ebitda for the quarter ending 2025-09-30 was $17.17M, a 125.61% increase year-over-year.
Privia Health Group, Inc. ebitda for fiscal 2025 was $44.14M, a 82.03% increase from fiscal 2024.
Privia Health Group, Inc. ebitda for fiscal 2024 was $24.25M, a 10.79% decline from fiscal 2023.
Privia Health Group, Inc. ebitda for fiscal 2023 was $27.18M, a change of $41.73M from fiscal 2022.
Privia Health Group, Inc. ebitda for fiscal 2022 was -$14.55M, a change of $200.42M from fiscal 2021.

Available history: 2019-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$15.13M	$11.77M	$3.36M	(m)	2.39%	(m)	$1.10M*	(m)	(m)	(m)	$7.02M
2026-03-31	Reported	$10.7M	$7.42M	$3.28M	(m)	1.77%	(m)	-$49.47M	(m)	(m)	(m)	$5.60M
2025-12-31	Reported	$13.94M	$11.28M	$2.66M	(m)	2.57%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$17.17M	$14.4M	$2.77M	(m)	2.96%	(m)	$51.99M*	(m)	(m)	(m)	$6.87M
2025-06-30	Reported	$5.92M	$3.34M	$2.58M	(m)	1.14%	(m)	$7.97M*	(m)	(m)	(m)	$2.46M
2025-03-31	Reported	$7.12M	$5.22M	$1.9M	(m)	1.48%	(m)	-$24.06M	(m)	(m)	(m)	$2.10M
2024-12-31	Reported	$7.08M	$5.25M	$1.83M	(m)	1.54%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$7.61M	$5.81M	$1.8M	(m)	1.74%	(m)	$33.15M*	(m)	(m)	(m)	$4.00M
2024-06-30	Reported	$6.92M	$5.1M	$1.82M	(m)	1.64%	(m)	$34.47M*	(m)	(m)	(m)	$3.42M
2024-03-31	Reported	$2.64M	$823,000.00	$1.82M	(m)	0.64%	(m)	-$33.14M	(m)	(m)	(m)	$751.00K
2023-12-31	Reported	$3.19M	$1.42M	$1.77M	(m)	0.72%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	$7.27M	$5.54M	$1.73M	(m)	1.74%	$18.00K*	$22.46M*	(m)	(m)	(m)	$2.49M
2023-06-30	Reported	$8.67M	$6.98M	$1.69M	(m)	2.10%	$72.00K*	$7.61M*	(m)	(m)	(m)	$1.44M
2023-03-31	Reported	$8.05M	$6.71M	$1.34M	(m)	2.09%	$0.00	-$13.38M	(m)	(m)	(m)	$2.13M
2022-12-31	Reported	$3.38M	$2.25M	$1.14M	(m)	0.93%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$3.42M	-$4.57M	$1.15M	(m)	-1.00%	$16.00K*	$16.14M*	(m)	(m)	(m)	-$4.84M
2022-06-30	Reported	-$4.09M	-$5.25M	$1.17M	(m)	-1.22%	$39.00K*	$7.22M*	(m)	(m)	(m)	$5.47M
2022-03-31	Reported	-$10.43M	-$11.55M	$1.12M	(m)	-3.32%	$34.00K	-$5.32M	(m)	(m)	(m)	$6.31M
2021-12-31	Reported	-$18.23M	-$19.35M	$1.11M	(m)	-6.62%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$12.34M	-$12.81M	$466,000.00	(m)	-4.91%	$197.00K*	$62.65M*	(m)	(m)	(m)	-$2.21M
2021-06-30	Reported	-$192.75M	-$193.19M	$440,000.00	(m)	-85.38%	$199.00K*	$7.20M*	(m)	(m)	(m)	-$20.00M
2021-03-31	Reported	$8.35M	$7.91M	$445,000.00	(m)	3.91%	$0.00	-$2.48M	(m)	(m)	(m)	$2.00M
2020-12-31	Reported	$4.62M	$4.16M	$454,000.00	(m)	2.16%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	$9M	$8.54M	$457,000.00	(m)	4.34%	$1.00K*	$35.54M*	(m)	(m)	(m)	-$8.56M
2020-06-30	Reported	$6.77M	$6.18M	$594,000.00	(m)	3.70%	$366.00K*	$13.77M*	(m)	(m)	(m)	$474.00K
2020-03-31	Reported	$6.83M	$6.5M	$338,000.00	(m)	3.21%	$13.00K	-$7.08M	(m)	(m)	(m)	$700.00K

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$44.14M	$34.24M	$9.91M	(m)	2.08%	(m)	$163.40M	(m)	(m)	(m)	$14.21M
2024-12-31	Reported	$24.25M	$16.98M	$7.27M	(m)	1.40%	(m)	$109.28M	(m)	(m)	(m)	$10.83M
2023-12-31	Reported	$27.18M	$20.65M	$6.53M	(m)	1.64%	$113.00K	$80.78M	(m)	(m)	(m)	$7.99M
2022-12-31	Reported	-$14.55M	-$19.12M	$4.57M	(m)	-1.07%	$104.00K	$47.20M	(m)	(m)	(m)	-$6.52M
2021-12-31	Reported	-$214.97M	-$217.44M	$2.46M	(m)	-22.25%	$547.00K	$55.06M	(m)	(m)	(m)	-$27.86M
2020-12-31	Reported	$27.22M	$25.38M	$1.84M	(m)	3.33%	$380.00K	$38.89M	(m)	(m)	(m)	-$7.44M
2019-12-31	Reported	$17.49M	$16.06M	$1.43M	(m)	2.22%	$5.71M	$24.36M	(m)	(m)	(m)	$1.21M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
GeneDx Holdings Corp. (WGS)	United States	$2.638B	-19.23
Pennant Group, Inc. (PNTG)	United States	$1.386B	39.84
U S PHYSICAL THERAPY INC /NV (USPH)	United States	$1.251B	32.48
Omada Health, Inc. (OMDA)	United States	$1.207B	309.08
InnovAge Holding Corp. (INNV)	United States	$1.206B	-635.60
Strata Critical Medical, Inc. (SRTA)	United States	$0.467B	11.33
LifeStance Health Group, Inc. (LFST)	United States	$4.510B	80.86
DocGo Inc. (DCGO)	United States	$0.034B	-0.25
VSEE HEALTH, INC. (VSEE)	United States	$0.003B
Agape ATP Corp (ATPC)		$0.002B